GHRP-6 Dosing Schedule: Titration, Timing, and Missed Doses

GHRP-6 at a glance:

• Drug class: Growth hormone secretagogue
• Route: subcutaneous injection (peptides) or oral (small molecules)
• Typical frequency: once daily to once weekly depending on agent
• Half-life: varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677)

The wrong GHRP-6 dose — too high, too low, or escalated too quickly — is the most common reason people stop the drug. FDA-approved agents have specific labeled dosing.

Standard Dosing Schedule for GHRP-6

FDA-approved agents have specific labeled dosing. Research-only GHS peptides have no validated human dosing.

The typical schedule for GHRP-6 is once daily to once weekly depending on agent via subcutaneous injection (peptides) or oral (small molecules). Half-life of varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677) explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For this class of compound, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms .

A typical titration plan for GHRP-6 holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of GHRP-6 is missed: for weekly schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677)) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in GHRP-6 side effects and the cost angle of dose escalation in GHRP-6 cost.

What the Trials Used

Published trial data for GHRP-6 comes primarily from: Stanley 2010 (tesamorelin in HIV-lipodystrophy); Nass 2008 (MK-677 in older adults).

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For GHRP-6: the standard contraindications for this drug class apply.

Bottom Line

Most GHRP-6 dose questions resolve in a 5-minute conversation with a clinician. Don't carry them around — get them answered.

Frequently Asked Questions

Related Reading

• GHRP-6 101: A Plain-English Guide for 2026
• GHRP-6 Side Effects Decoded: What's Normal vs. What Isn't
• Does GHRP-6 Really Work? An Evidence-Based Results Review
• The Real GHRP-6 Price Tag in 2026 — With and Without Insurance
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.
• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.
• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.

This page is informational only and is not medical advice. We do not provide guidance for self-administration of compounds that are not FDA-approved.